MacroGenics to Participate in Upcoming Investor Conferences

Rhea-AI Summary

MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company specializing in innovative cancer therapeutics, will present at three key investor conferences this September 2022. CEO Scott Koenig, M.D., Ph.D., will participate in the Citi 17th Annual BioPharma Conference on September 7 at 2:40 pm ET, the H.C. Wainwright 24th Annual Global Investment Conference on September 12 at 10:30 am ET, and the Guggenheim Nantucket Therapeutics Conference on September 28 at 2:30 pm ET. Webcasts will be available on the company's website.

ROCKVILLE, MD, Sept. 02, 2022 (GLOBE NEWSWIRE) --

MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will participate in the following investor conferences in September 2022:

• Citi 17^th Annual BioPharma Conference (Boston). MacroGenics’ President & Chief Executive Officer, Scott Koenig, M.D., Ph.D., will participate in the Bispecific Panel on Wednesday, September 7, 2022, at 2:40 pm ET. Management will also participate in one-on-one meetings.
• H.C. Wainwright 24^th Annual Global Investment Conference (New York). MacroGenics’ President & Chief Executive Officer, Scott Koenig, M.D., Ph.D. will provide a corporate overview on Monday, September 12, 2022, at 10:30 am ET. MacroGenics’ management will also participate in one-on-one meetings.
• Guggenheim Nantucket Therapeutics Conference. MacroGenics’ President & Chief Executive Officer, Scott Koenig, M.D., Ph.D., will participate in a fireside chat on September 28, 2022, at 2:30 pm ET and participate in one-on-one meetings.

Webcasts of the above will be made available under “Events & Presentations” in the Investor Relations section of MacroGenics’ website at http://ir.macrogenics.com/events.cfm.   The Company maintains archived replays of webcasts on its website for 30 days after the conference.

About MacroGenics, Inc.
MacroGenics (the Company) is a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the treatment of cancer. The Company generates its pipeline of product candidates primarily from its proprietary suite of next-generation antibody-based technology platforms, which have applicability across broad therapeutic domains. The combination of MacroGenics' technology platforms and protein engineering expertise has allowed the Company to generate promising product candidates and enter into several strategic collaborations with global pharmaceutical and biotechnology companies. For more information, please see the Company's website at www.macrogenics.com. MacroGenics and the MacroGenics logo are trademarks or registered trademarks of MacroGenics, Inc.

###

FAQ

When will MacroGenics participate in the Citi 17th Annual BioPharma Conference?

MacroGenics will participate in the Citi 17th Annual BioPharma Conference on September 7, 2022, at 2:40 pm ET.

What is the schedule for the H.C. Wainwright 24th Annual Global Investment Conference for MacroGenics?

MacroGenics will present at the H.C. Wainwright 24th Annual Global Investment Conference on September 12, 2022, at 10:30 am ET.

When will the Guggenheim Nantucket Therapeutics Conference take place for MacroGenics?

The Guggenheim Nantucket Therapeutics Conference will occur on September 28, 2022, with MacroGenics presenting at 2:30 pm ET.

Where can I find webcasts of the MacroGenics investor conference presentations?

Webcasts of the MacroGenics investor conferences will be available under 'Events & Presentations' in the Investor Relations section of their website.

What is the focus of MacroGenics as a biopharmaceutical company?

MacroGenics focuses on developing and commercializing innovative antibody-based therapeutics primarily for cancer treatment.